Related Experiment Video
Updated: Aug 6, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
The benefit of treating isolated systolic hypertension
1Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, B-3000 Leuven, Belgium.
Insights
Antihypertensive drug treatment is beneficial for individuals over 60 with isolated systolic hypertension (ISH). Treatment is recommended when systolic blood pressure consistently measures 160 mm Hg or higher.
Area of Science:
- Cardiology
- Geriatrics
- Public Health
Background:
- Isolated systolic hypertension (ISH) affects over 15% of individuals older than 60.
- ISH is a significant, modifiable cardiovascular risk factor in the elderly.
- Elevated systolic blood pressure increases adverse cardiovascular event risk.
Purpose of the Study:
- To evaluate the efficacy of antihypertensive drug treatment in older adults with ISH.
- To synthesize evidence from multiple placebo-controlled trials on ISH management.
Main Methods:
- Meta-analysis of pooled patient data from three major trials: SHEP, Syst-Eur, and Syst-China.
- Inclusion of a subset of patients with ISH from five additional elderly trials.
- Total pooled sample size of 15,693 older patients with ISH.
Main Results:
- Antihypertensive drug treatment demonstrated significant benefits in reducing cardiovascular risk in the elderly with ISH.
- Pooled results confirm the efficacy of pharmacological intervention for ISH.
- The benefit of treatment was clearly established for systolic blood pressure >= 160 mm Hg.
Conclusions:
- Antihypertensive drug treatment is justified for older patients with ISH.
- Consistent systolic blood pressure readings of 160 mm Hg or higher warrant treatment.
- Managing ISH in the elderly is crucial for cardiovascular risk reduction.
Abstract:
Isolated systolic hypertension affects over 15% of all people older than 60 years of age. In the elderly, systolic hypertension is a major modifiable cardiovascular risk factor. Systolic blood pressure is associated with higher risk of an adverse outcome. Diastolic blood pressure is inversely correlated with total mortality, independent of systolic blood pressure, highlighting the role of pulse pressure as risk factor. Three placebo-controlled outcome trials on antihypertensive drug treatment in older patients with isolated systolic hypertension have been published: the Systolic Hypertension in the Elderly Program (SHEP), the Systolic Hypertension in Europe (Syst-Eur) Trial, and the Systolic Hypertension in China (Syst-China) Trial. These three trials showed the benefit of antihypertensive drug treatment. A meta-analysis was done by pooling the patients from these three trials with a subset of patients with isolated systolic hypertension from five other trials in the elderly. The pooled results of 15,693 older patients with isolated systolic hypertension prove that antihypertensive drug treatment is justified if systolic blood pressure on repeated clinic measurements is 160 mm Hg or higher.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension IV: Drug Therapy and Lifestyle Modifications

